%D9%85%D9%8A%D9%84%D8%A7%D8%B1%D8%B3%D9%88%D8%A8%D8%B1%D9%88%D9%84%D9%85%D9%84%D8%A7%D8%B1%D8%B2%D9%88%D9%BE%D8%B1%D9%88%D9%84Category:MelarsoprolMelarsoprolMelarsoprolMelarsoprolMelarsoproliM%C3%A9larsoprolMelarsoprol%E3%83%A1%E3%83%A9%E3%83%AB%E3%82%BD%E3%83%97%E3%83%AD%E3%83%BC%E3%83%ABMelarsoprol%E0%AC%AE%E0%AD%87%E0%AC%B2%E0%AC%BE%E0%AC%B0%E0%AC%B8%E0%AD%8B%E0%AC%AA%E0%AD%8D%E0%AC%B0%E0%AD%8B%E0%AC%B2MelarsoprolMelarsoprolMelarsoprol%D0%9C%D0%B5%D0%BB%D0%B0%D1%80%D1%81%D0%BE%D0%BF%D1%80%D0%BE%D0%BBMelarzoprolMelarzoprolMelarsoprolQ419753
about
Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasisEquivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sicknessArsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patientsGenotypic status of the TbAT1/P2 adenosine transporter of Trypanosoma brucei gambiense isolates from Northwestern Uganda following melarsoprol withdrawalSafety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sicknessAquaporin 2 mutations in Trypanosoma brucei gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprolMelarsoprol sensitivity profile of Trypanosoma brucei gambiense isolates from cured and relapsed sleeping sickness patients from the Democratic Republic of the CongoMelarsoprol-cyclodextrins inclusion complexes.Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial.Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis.Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis.Chimerization at the AQP2-AQP3 locus is the genetic basis of melarsoprol-pentamidine cross-resistance in clinical Trypanosoma brucei gambiense isolates.Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001.Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomesNovel therapeutic approach: organic arsenical melarsoprol) alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo.High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo.Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the CongoDrug resistance in African trypanosomiasis: the melarsoprol and pentamidine story.The melaminophenyl arsenicals melarsoprol and melarsen oxide interfere with thiamine metabolism in the fission yeast Schizosaccharomyces pombe.[Melarsoprol][Routes and kinetics of arsenic elimination in rats after administration of organoarsenic drugs. IV. Biliary excretion of melarsoprol, melarsonyl and related compounds][Routes and kinetics of arsenic elimination in rats after administration of organic arsenic compounds. II. Study of melarsoprol and potassic melarsonyl]Front-line glioblastoma chemotherapeutic temozolomide is toxic to Trypanosoma brucei and potently enhances melarsoprol and eflornithine.Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes.Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy.Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment.Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda.Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda.[Therapeutic failure of melarsoprol among patients treated for late stage T.b. gambiense human African trypanosomiasis in Uganda]Susceptibility of Ugandan Trypanosoma brucei rhodesiense isolated from man and animal reservoirs to diminazene, isometamidium and melarsoprol.Melarsoprol- and pentamidine-resistant Trypanosoma brucei rhodesiense populations and their cross-resistance.Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis.Alternative application of melarsoprol for treatment of T. B. gambiense sleeping sickness. Preliminary results.Pharmacokinetics of melarsoprol in uninfected vervet monkeys.Pharmacokinetic properties of the trypanocidal drug melarsoprol.An in vitro bioassay for quantification of melarsoprol in serum and cerebrospinal fluid.Human African trypanosomiasis: diagnosis, relapse and survival after severe melarsoprol-induced encephalopathy.Investigations of the metabolites of the trypanocidal drug melarsoprol.Physico-chemical properties of the trypanocidal drug melarsoprol.Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate.
P921
Q27306003-43365DA4-02D2-4933-88A5-9F1C29300804Q28281992-63E1C941-BA79-4C0B-9482-3F6020D54E57Q28370994-F7DA968C-9961-408E-BA08-B2F74C569129Q28476222-C8BC6828-4EB9-485D-A8F1-9E048197AF20Q28483501-A0DDF3B4-7B17-45BC-9521-9B7374ED2786Q28534313-D0DCCC6E-EEB6-49F2-8F3F-78992595B900Q28543489-C06F9C6D-4192-41A7-BD23-B97D07150D08Q31013660-4568A76D-0345-496F-AF92-11641226B0E2Q33900237-03CA91CE-C834-4BF1-8248-529644F846F2Q33989166-CB45344D-72E4-4670-8968-56256D11B738Q35126182-282F72B0-11DC-4D17-A5D3-0320B3C9677BQ35645101-4746C6B7-3A0D-4C2B-A204-4F39AB5B062BQ36009318-CC7F5B0A-9696-466B-A63F-A7BE5EF0E060Q36079376-71510718-0F93-4329-8ADF-FD304DBB31EEQ36621084-77779BB6-F899-44C4-A34F-5A9547331895Q37009244-8CA491E2-6DDF-4383-A16E-7869B271AF3FQ37063841-71900214-0778-41CA-92CE-884487D9F3BEQ37317284-06B4F111-FEB4-4AFF-A442-35FECB201EB9Q37489213-5FA5AAC9-C5D9-4992-A087-38A4260F9ED3Q38499727-6DE4C720-BF68-46B4-ABC7-679C41C86605Q38516525-12FC76CF-5535-4A99-A98C-00F6884DA3FCQ38516556-D092D6C2-A457-4A22-8BA0-DE51B9F689E9Q38759218-B0B813D8-E261-4F00-9DA7-BAD7AC688862Q38875419-24043278-C0CF-4B74-8A78-8EA037321224Q38884977-0E9CA84F-2F56-4352-B1FE-6B295D8A9EFCQ38885263-E0F391BF-E658-4C8E-9FE7-0639D8985F4EQ38885267-8C460066-3072-416C-AA0D-C527AC0D4FFBQ38886219-89BD7E24-8CE0-462E-9172-BBC75536649CQ38886515-DB4D3D2E-B86E-404F-AF19-7283A8877147Q38888001-29E020FC-041E-40D4-8A37-6BB19523421BQ38905903-15AB3372-8D76-4744-8E41-CC0F0D1A93B4Q38912273-8B5DD203-907B-492C-A75D-3569B47BA363Q38926666-68756CDD-54C8-4E10-8C5E-4BE98C33D345Q38926670-5B1D82DA-BC60-4E76-9F0D-E7D7CEF0149DQ38926674-DCD3ACCD-3BE7-4F48-9FAC-DF966934216BQ38926678-5911ED4F-6470-4C12-960E-2F37AC7D5587Q38940879-73F40D2E-B0E1-4FC6-BB0C-D20E2D076A28Q39126778-89BFAC91-1CD4-4EF0-B6EE-81020AC8A218Q39126784-20D1ABE5-840B-421E-A42D-91913CCEB7F8Q39212746-086B7968-6F3F-486D-8468-167CAAC03860
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Melarsoprol
@de
Melarsoprol
@es
Melarsoprol
@it
Melarsoprol
@nl
Melarsoprol
@pl
Melarsoprol
@ro
Melarsoprol
@vi
Melarsoproli
@fi
Melarzoprol
@sh
Melarzoprol
@sr
type
label
Melarsoprol
@de
Melarsoprol
@es
Melarsoprol
@it
Melarsoprol
@nl
Melarsoprol
@pl
Melarsoprol
@ro
Melarsoprol
@vi
Melarsoproli
@fi
Melarzoprol
@sh
Melarzoprol
@sr
altLabel
494-79-1
@fr
C12H15AsN6OS2
@fr
Mel B
@es
Melarsoprol
@en
prefLabel
Melarsoprol
@de
Melarsoprol
@es
Melarsoprol
@it
Melarsoprol
@nl
Melarsoprol
@pl
Melarsoprol
@ro
Melarsoprol
@vi
Melarsoproli
@fi
Melarzoprol
@sh
Melarzoprol
@sr
P31
P486
P592
P6366
P646
P661
P662
P683
P1417
science/melarsoprol
P2067
P231
P232
P233
C1C(S[As](S1)C2=CC=C(C=C2)NC3=NC(=NC(=N3)N)N)CO
P234
1S/C12H15AsN6OS2/c14-10-17-11( ...... H,5-6H2,(H5,14,15,16,17,18,19)
P235
JCYZMTMYPZHVBF-UHFFFAOYSA-N
P2566
100.007.086
P267
P274
C₁₂H₁₅AsN₆OS₂